People with HIV who have belly fat and are on medication to control the virus who took tesamorelin did not show a significant improvement in thinking skills compared to those who received usual care...

In people with HIV who have belly fat and are on medication to control the virus, changes in IGF-1 levels from tesamorelin treatment did not relate to changes in thinking skills or waist size. This finding is from the abstract summary - full study details were not available

People with HIV who have belly fat and are on medication to control the virus who took tesamorelin had a waist size that was about 2.7 centimeters smaller on average compared to those who didn't, and this difference was statistically significant. This finding is from the abstract summary - full study details were not available

HIV patients with belly fat who took tesamorelin were more likely to lose at least 8% of their visceral fat than those who took a placebo.

If the drug doesn’t shrink your belly fat by at least 8%, it won’t make your fat look healthier on scans — you have to respond to the drug for this benefit.

HIV patients with belly fat who took tesamorelin had a 69% chance of losing at least 8% visceral fat, while those on placebo had only a 33% chance, showing a clear benefit from the drug.